50 results about "LIVER FATTY DEGENERATION" patented technology

The invention discloses Bifidobacterium adolescentis CCFM1061, its fermented food and a preparation method of bacterial preparations. Bifidobacterium adolescentis CCFM1061 can significantly improve liver damage in patients with non-alcoholic fatty liver disease, reduce serum ALT levels, and reduce hepatic steatosis and hepatic ballooning. lesions and hepatic lobular inflammation; it can significantly alleviate the increase in serum total cholesterol, blood sugar, liver triglyceride and low-density protein cholesterol caused by high-fat diet in patients with nonalcoholic fatty liver disease; at the same time, it can significantly improve liver It can significantly increase the expression of Nrf2 gene in fatty liver cells; improve the fasting blood sugar in type 2 diabetic mice; in addition, Bifidobacterium adolescent CCFM1061 has a strong adsorption capacity for PFOA, which reduces the absorption of PFOA in the body and has the effect of relieving PFOA toxicity capacity.

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

The invention provides Lactobacillus paracasei B111H and its application in metabolic syndrome, and relates to the technical field of microorganisms and its application. The strain of Lactobacillus paracasei is preserved in the General Microbiology Center of the China Committee for the Collection of Microorganisms, with the preservation number: CGMCC No: 22184; the preservation time is: April 14, 2021. Lactobacillus paracasei of the present invention is isolated and screened from human feces, has the effect of significantly inhibiting lipid accumulation in liver cells, reducing body weight and blood lipid levels, and improving hepatic steatosis. The occurrence of liver has important application significance. The discovery of the strain provides a new microbial resource for lipid-lowering foods or medicines.

The invention discloses application of methyl palmitate in preparing a drug for preventing or treating fatty liver. Compared with the prior art, the invention finds that the methyl palmitate can be used for preventing or treating the fatty liver and particularly for non-alcohol fatty liver for the first time, and the treatment effect is significant. The research proves that the methyl palmitate can alleviate the liver fatty degeneration, inflammation and fibrosis, can alleviate the abnormal accumulation of liver lipid and can reduce the oxidation stress.

The invention belongs to the field of traditional Chinese medicines and relates to a traditional Chinese compound medicament. The traditional Chinese compound medicament disclosed by the invention is prepared from atractylodes macrocephalaon polysaccharide, jasminoidin and chlorogenic acid in weight ratio of (100-500):(10-150):(1-50). The traditional Chinese compound medicament is produced into oral solid preparations such as granules, tablets and capsules by using a conventional method. Through a high fat die-induced rat fatty liver model experiment, screening applying uniform design and repeated verification, the results show that the traditional Chinese compound medicament has the efficacies that the content of triglyceride of a rat liver tissue in the model can be remarkably reduced, the liver fatty degeneration degree and liver damage are alleviated and no remarkable effect is achieved by a single component; and the compound medicament can be used for preparing medicaments for preventing and controlling simple fatty liver and fatty hepatitis or can be used for preparing medicaments for preventing and controlling the fatty liver diseases.

The invention relates to a medicine for treating liver depression and spleen deficiency syndromes and in particular provides a pharmaceutical composition for treating liver depression and spleen deficiency syndromes as well as a preparation method and application thereof. The pharmaceutical composition for treating the liver depression and spleen deficiency syndromes contains the following components: astragalus, processed bighead atractylodes rhizome, raw coix seed, salviae miltiorrhizae, rhizoma cyperi, radix bupleuri, oriental wormwood, polygonum cuspidatum, concha arcae, verbena, semen cassiae, raw hawthorn and fructus polygoni orientalis. The pharmaceutical composition for treating liver depression and spleen deficiency syndromes has the following effects when applied to a patient suffering from non-alcoholic type fatty liver disease (NAFLD): clinical symptoms and signs of the NAFLD patient are obviously alleviated; liver function and blood lipid parameters of the patient can be safely and effectively reduced, and the effects of protecting the liver, lowering transaminase and lowering lipid are realized; and hepatic steatosis degree of the patient is obviously reduced.

The invention discloses application of maca and moringa oleifera in treatment of alcoholic fatty liver, and belongs to the field of traditional Chinese medicines. The invention proves that maca and moringa oleifera can intervene in alcoholic fatty liver disease, can significantly reduce serum biochemical indexes such as ALT, TC, TG and the like, and can improve liver fatty degeneration and reduce lipid droplets; according to the invention, a new direction is expanded for the research of the efficacy of the maca and the moringa oleifera, and a new research medicine is provided for the treatment intervention of the alcoholic fatty liver.